Hikma Pharmaceuticals (LON:HIK) Reaches New 12-Month High – Still a Buy?

Hikma Pharmaceuticals PLC (LON:HIK)’s share price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as GBX 2,356 ($29.61) and last traded at GBX 2,338 ($29.38), with a volume of 1704184 shares. The stock had previously closed at GBX 2,308 ($29.01).

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upped their target price on shares of Hikma Pharmaceuticals from GBX 2,400 ($30.16) to GBX 2,560 ($32.17) and gave the stock a “buy” rating in a research note on Wednesday, January 29th.

Hikma Pharmaceuticals Stock Down 0.2 %

The stock has a market cap of £6.48 billion, a PE ratio of 22.92, a PEG ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The company has a 50 day moving average price of GBX 2,074.95 and a two-hundred day moving average price of GBX 1,978.88.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.